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We commend Kearns et al. for their compelling study 
demonstrating non-inferiority of spinal morphine to fasica iliaca 
block (FIB) [1]. We would like to invite the authors to comment 
on some further questions we have about this paper. 
Firstly, nonsteroidal anti-inflammatory drugs (NSAIDs) 
are well known to be opioid-sparing, reducing the consumption 
of morphine by 30-50% [2]. Do the authors have data on any 
difference between treatment groups pre- and postoperatively 
in NSAID consumption? 
Secondly, the authors reported a non-significant 
(p=0.1464, Fishers exact test) difference in preoperative 
paracetamol consumption between treatment groups. Given 
that pain is a prominent feature prompting hip arthroplasty, 
could the authors comment on whether relative changes in 
pain scores might have been more appropriately reported than 
absolute pain scores? 
Finally, the authors suggest that a fascia iliaca block has 
a low complication rate, justifying the use of sham fascia iliaca 
blocks. However, in their study there was one incidence of 
temporary femoral nerve palsy (1 in 54). The sensory, motor 
and/or functional effects are not described, but this 
complication is important in a group of patients where a key 
aim of the surgical intervention is ambulation. Given that FIB 
does not offer any analgesic advantage (or perhaps even any 
analgesia [4]) over spinal morphine for hip arthroplasties, do 
the authors consider FIB to be too risky for hip patients? Also, if 
there is risk but no clear benefit of fascia iliaca for hip 
arthroplasty, do the authors think it was justified to use sham 
fascia iliaca blocks in this study? 
  
M. Haque 
T. Fregene 
 
 
We thank Dr Haque and Fregene for their interest in our study.   
As stipulated in our protocol,1 patients taking NSAIDs pre-operatively 
continued to take these medications. No NSAIDs were commenced de novo 
in either treatment group during the study period.  Data relating to NSAID 
use were not recorded and unfortunately we cannot provide this additional 
information. 
The difference in pre-operative paracetamol consumption referred to the 
pre-medicant dose prescribed as part of the study protocol and not 
patients’ usual medications. Unfortunately, not all patients received pre-
operative paracetamol. The staff members who were responsible for 
administering the paracetamol had no knowledge of the treatment 
allocation and therefore any omissions were entirely random and should 
have affected each group equally. In the spinal morphine group, 64.7% of 
patients received pre-operative paracetamol while in the fascia ililaca 
group, this was slightly greater at 78.8% (p 0.17). All patients were 
prescribed regular paracetamol post-operatively. Whilst more patients in 
the fascia iliaca group received paracetamol pre-operatively, it seems 
unlikely that this would have significantly altered the results of the study. 
As patients in the fascia iliaca group had inferior analgesia despite the 
above theoretical advantage, this reinforces the result of the primary 
outcome further. We did not collect pain scores pre-operatively as these 
scores would have related to patients’ underlying hip pathology rather than 
the post-surgical pain they experienced after surgery. As the study was 
randomised, we would not have expected significant differences between 
groups for pre-operative pain scores.   
 
We agree that any neuropraxia is a serious adverse event and reported this 
as such. The patient in this case made a full recovery. The incident of 
femoral nerve palsy was discussed at length with the surgical team who did 
not consider it likely to have resulted from the study intervention. The 
incidence of surgery related femoral nerve palsy is reported as 0.1-2.4% 
with a mean of 0.8%.2 It is therefore difficult in practice to establish 
whether surgery or anaesthesia is causative. The fascia iliaca block is 
considered a relatively low risk procedure and is approved for use by non-
medical practitioners in National guidelines.3 Any patient undergoing a 
nerve block should be counselled regarding the risks and benefits in each 
case.   
 
The issue of sham blocks remains controversial. We accept that the fascia 
iliaca block is not without risk and patients were informed and consent 
obtained for the possibility of being administered a sham nerve block. We 
ensured that the study underwent extensive peer review via grant 
applications and publication of the protocol.1 It has been suggested that the 
use of any sham treatment be evaluated using the “SHAM tool”.4 This aims 
to establish and minimise any risk of harm to the patient. This tool was first 
published in 2011, and unfortunately was not available at the time of our 
study being designed and undergoing ethical review (October 2010). 
However, in light of the SHAM recommendations, we would not use sham 
blocks in future study designs.  
 
Finally, the role of FIB as an adjunct to spinal morphine pre-operatively for 
THR has not been investigated and more information is required before 
making any firm recommendations. 
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